ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1520

DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome

Abhishek Nandan1, Huzaefah Syed1, Josna Haritha2, David Maniscalco1, Rabia Gill1, Puneet Puri1 and Vivana Rodriguez1, 1Virginia Commonwealth University Health System, Richmond, VA, 2University of Chicago Medicine, Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: DMARDs, hepatic disorders and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hepatotoxicity is a common reason why DMARDs are abandoned or changed in RA. We hypothesize that features of metabolic syndrome (such as obesity, dyslipidemia, and diabetes) are risk factors for DMARD hepatotoxicity in RA.

Methods:   We conducted a retrospective chart review of 361 patients with RA listed as the primary diagnosis code for ≥ 3 consecutive visits. Demographic information, BMI, lipid panel, prior alcohol use, smoking status, viral hepatitis serologies, statin use, seropositive status, and type of DMARD used were recorded at the initial visit. Patients with active hepatitis B and C were excluded from analysis. DMARD hepatotoxicity was defined as change of DMARD or dose decrease of DMARD with corresponding provider documentation of concern for hepatotoxicity. Using exact logistic regression, odds ratios for the risk factors of DMARD hepatotoxicity were calculated.

Results: Out of the 361 patients reviewed: 15.1% had BMI > 35 and 17.8% had a diagnosis of diabetes mellitus II. Table 1 has additional baseline information. 20 of 361 patients (5.5 %) had DMARD hepatotoxicity. Methotrexate (OR 3.07) and leflunomide (OR 6.11) were significantly associated with risk of DMARD hepatotoxicity. Figure 1 demonstrates the adjusted odds ratios for BMI, diabetes, and alcohol abuse as risk factors for DMARD hepatotoxicity. HDL ≤ 40 had an unadjusted OR of 2.98 (0.74 – 12; p 0.119) toward being a risk factor for DMARD hepatotoxicity. RF or anti-CCP seropositivity, statin-use, age, and sex did not demonstrate a correlation value to suggest they are risk factors.

Conclusion: Our study does suggest that several surrogates of metabolic syndrome such as BMI and diabetes mellitus are likely risk factors for development DMARD hepatotoxicity, especially with methotrexate and leflunomide. Though the study was underpowered for the statistical significance on some of these variables, clinicians should consider features of metabolic syndrome as potential risk factors for hepatotoxicity with DMARD use. Further studies need to be performed examining this relationship.


Disclosure: A. Nandan, None; H. Syed, None; J. Haritha, None; D. Maniscalco, None; R. Gill, None; P. Puri, None; V. Rodriguez, None.

To cite this abstract in AMA style:

Nandan A, Syed H, Haritha J, Maniscalco D, Gill R, Puri P, Rodriguez V. DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/dmard-hepatotoxicity-in-rheumatoid-arthritis-and-its-association-with-the-surrogates-of-metabolic-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dmard-hepatotoxicity-in-rheumatoid-arthritis-and-its-association-with-the-surrogates-of-metabolic-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology